Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
The ONCT news page on Stock Titan aggregates press releases and other coverage related to Oncternal Therapeutics, Inc., a company that has been described in its own communications as a clinical-stage biopharmaceutical developer of oncology therapies. These news items trace both the evolution of its investigational pipeline and its later strategic decisions, giving investors and researchers a consolidated view of the company’s trajectory.
Earlier news focuses on clinical and operational updates for programs such as ONCT-534, an investigational dual-action androgen receptor inhibitor evaluated in metastatic castration-resistant prostate cancer, and ONCT-808, an autologous CAR T cell therapy targeting ROR1 in relapsed or refractory aggressive B-cell lymphoma. Releases detail dose-escalation cohorts, safety and tolerability observations, interim efficacy signals based on measures like prostate-specific antigen levels, and protocol amendments in ongoing Phase 1/2 studies.
Other articles describe the broader pipeline, including zilovertamab, a monoclonal antibody targeting ROR1 studied in combination with ibrutinib and in investigator-initiated trials, and ONCT-216, a small-molecule inhibitor of ETS family oncoproteins with regulatory designations for Ewing sarcoma. These pieces provide context on the scientific rationale and clinical settings in which the agents have been tested.
More recent news documents a shift in corporate direction. A September 2024 press release announces the termination of clinical studies for ONCT-534 and ONCT-808, the discontinuation of product development activities and the exploration of strategic alternatives. A July 2025 release reports the sale of the zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. and states that a new executive will oversee the winddown of Oncternal’s operations. Together, these items form a historical record of how the ONCT story moved from active clinical development toward asset sales and an operational wind-down.
Users interested in ONCT news can review this stream to understand the company’s investigational programs, clinical milestones, strategic reviews and the subsequent wind-down steps described by Oncternal in its own announcements.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to Ariadne Jerue as the new Associate Director of Clinical Operations. This award, consisting of options to purchase 28,400 shares, follows Oncternal’s 2021 Employment Inducement Incentive Award Plan. The options will vest over four years, with an exercise price based on the stock’s closing price at the grant date. The award aims to attract new talent in the competitive biopharmaceutical sector.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) received FDA clearance for its Phase 1/2 IND application for ONCT-808, a CAR T therapy targeting ROR1 in patients with aggressive B cell non-Hodgkin's lymphoma. This marks a significant step for the company, focusing on patients who have previously failed CD19 CAR T treatment. The study is expected to begin soon, with interim results set to be presented at a scientific conference in 2023. Oncternal is also progressing in its study of zilovertamab, another therapy targeting ROR1, further expanding its oncology pipeline.
Oncternal Therapeutics announced the initiation of its Phase 3 global study, ZILO-301 (NCT05431179), for zilovertamab, targeting relapsed/refractory mantle cell lymphoma (MCL). The study, the first to evaluate this novel therapy, aims to enroll 365 patients across 50-100 sites globally, with screening and enrollment expected to begin soon following IRB approval. The trial will assess the drug's efficacy alongside ibrutinib, with key endpoints including Objective Response Rate (ORR) and progression-free survival (PFS). Interim results aim to support a BLA submission for faster FDA approval.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced its participation in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022, in New York City. CEO James Breitmeyer will join the "Multiple Myeloma & Lymphoma" panel at 4:15 PM (ET) and conduct one-on-one meetings. Oncternal is focused on developing innovative oncology therapies, with its lead program, zilovertamab, aimed at hematological malignancies and prostate cancer.
Oncternal Therapeutics (Nasdaq: ONCT) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO James Breitmeyer will present a corporate overview starting September 12th at 7:00am (ET), available on demand. The presentation can be accessed for 30 days on their investor website. Oncternal is focused on developing novel oncology therapies, including zilovertamab for hematological cancers and ONCT-808, a CAR-T cell therapy.
Oncternal Therapeutics reported promising interim results from its Phase 1/2 study of zilovertamab combined with ibrutinib for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). This combination showed an 85% objective response rate and a 41% complete response rate in MCL patients, significantly higher than historical data for ibrutinib alone. The company has cash reserves of $78.9 million, expected to last into the first half of 2024. Upcoming milestones include the initiation of the Phase 3 study ZILO-301 in September 2022 and IND submissions for ONCT-808.
Oncternal Therapeutics (Nasdaq: ONCT) announced it will release its second quarter 2022 financial results after the market closes on August 9, 2022. A management webcast will follow at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results and provide a business update.
The company focuses on developing innovative oncology therapies, particularly targeting hematological malignancies and prostate cancer, with products like zilovertamab and ONCT-808 in various stages of clinical development.
Oncternal Therapeutics announced a collaboration with Pharmacyclics to support its Phase 3 trial, ZILO-301, for treating relapsed or refractory mantle cell lymphoma (MCL) with zilovertamab and ibrutinib. The agreement will provide ibrutinib and facilitate ZILO-301's initiation in Q3 2022. Zilovertamab, a monoclonal antibody targeting ROR1, aims to address unmet medical needs in oncology. This collaboration underscores Oncternal's strategic pursuit of impactful cancer therapies as it progresses through critical clinical trials.
Oncternal Therapeutics (Nasdaq: ONCT) announced the presentation of preclinical data on its ROR1-targeting cell therapies at the EHA 2022 Hybrid Congress. This includes work from the Karolinska Institutet, showing ROR1 CAR-T and NK cells can recognize targets and exhibit anti-tumor activity in mantle cell lymphoma models. The company is advancing its lead therapy, ONCT-808, towards an Investigational New Drug application, with the first patient expected to be dosed soon. Zilovertamab, another candidate, is under evaluation in multiple clinical trials.
Oncternal Therapeutics (Nasdaq: ONCT) announced a poster presentation for its Phase 3 ZILO-301 clinical trial, evaluating zilovertamab combined with ibrutinib in treating relapsed or refractory mantle cell lymphoma (R/R MCL). This trial aims to prove superior efficacy over ibrutinib alone. Interim data showcased an objective response rate (ORR) of 85% and a complete response rate (CR) of 41%, significantly higher than the historical rates of 66% and 20%, respectively. The trial initiates in Q3 2022, targeting approximately 250 patients.